JACQUELYN MARTIN: Open Payments
NPI 1386819373 · HOT SPRINGS, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$653 in 25 payments from 9 companies in 2025. Trend: 2023 $391 · 2024 $480 · 2025 $653
Food & beverage: $653
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 8 | $218 |
| Supernus Pharmaceuticals, Inc. | 3 | $103 |
| Lundbeck LLC | 3 | $88 |
| ABBVIE INC. | 4 | $83 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $59 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $36 |
| E.R. Squibb & Sons, L.L.C. | 1 | $26 |
| Tris Pharma Inc | 1 | $21 |
| Collegium Pharmaceutical, Inc. | 1 | $19 |
Products named: INGREZZA, Qelbree, REXULTI, VRAYLAR, CAPLYTA, TRINTELLIX, COBENFY, Dyanavel XR.
Industry payments across AR — which companies pay providers there.
